GlassScriptPhysician profile
Sandra L Hollander
NPI 1225168248
$5,810.51
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $1,056 · 2021: $1,497 · 2022: $1,812 · 2023: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $734.25 | 2019-2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $615.66 | 2019-2023 | |
| Amgen INC. | $516.48 | 2019-2022 | |
| Coherus Oncology, INC. | $448.09 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $413.87 | 2019-2022 | |
| Daiichi Sankyo INC. | $379.57 | 2019-2023 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $312.52 | 2019-2022 | |
| Incyte Corporation | $260.26 | 2019-2023 | Jakafi |
| Glaxosmithkline, LLC. | $217.56 | 2020-2023 | |
| Genzyme Corporation | $154.78 | 2019-2022 | |
| Janssen Biotech, INC. | $148.62 | 2019-2023 | Imbruvica, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $107.82 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $95.89 | 2021-2022 | |
| Celgene Corporation | $95.79 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $82.34 | 2020-2023 | Xpovio |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Hollander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.